| 1,10-Phenanthroline | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with 1,10-Phenanthroline. | Experimental |
| Aceclofenac | The risk or severity of adverse effects can be increased when Aceclofenac is combined with 19-norandrostenedione. | Approved |
| Acetylsalicylic acid | The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with 19-norandrostenedione. | Approved, Vet Approved |
| Adapalene | The risk or severity of adverse effects can be increased when Adapalene is combined with 19-norandrostenedione. | Approved |
| Aldesleukin | 19-norandrostenedione may decrease the antineoplastic activities of Aldesleukin. | Approved |
| Aluminum hydroxide | The bioavailability of 19-norandrostenedione can be decreased when combined with Aluminum hydroxide. | Approved |
| Ambenonium | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ambenonium. | Approved |
| Aminosalicylic Acid | The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with 19-norandrostenedione. | Approved |
| Amiodarone | The serum concentration of 19-norandrostenedione can be increased when it is combined with Amiodarone. | Approved, Investigational |
| Amphotericin B | 19-norandrostenedione may increase the hypokalemic activities of Amphotericin B. | Approved, Investigational |
| Andrographolide | The risk or severity of adverse effects can be increased when HMPL-004 is combined with 19-norandrostenedione. | Investigational |
| Antipyrine | The risk or severity of adverse effects can be increased when Antipyrine is combined with 19-norandrostenedione. | Approved |
| Apremilast | The risk or severity of adverse effects can be increased when Apremilast is combined with 19-norandrostenedione. | Approved, Investigational |
| Aprepitant | The serum concentration of 19-norandrostenedione can be increased when it is combined with Aprepitant. | Approved, Investigational |
| Atazanavir | The serum concentration of 19-norandrostenedione can be increased when it is combined with Atazanavir. | Approved, Investigational |
| Atracurium besylate | Atracurium besylate may increase the adverse neuromuscular activities of 19-norandrostenedione. | Approved |
| Azapropazone | The risk or severity of adverse effects can be increased when Azapropazone is combined with 19-norandrostenedione. | Withdrawn |
| Azelastine | The risk or severity of adverse effects can be increased when Azelastine is combined with 19-norandrostenedione. | Approved |
| Balsalazide | The risk or severity of adverse effects can be increased when Balsalazide is combined with 19-norandrostenedione. | Approved, Investigational |
| Bazedoxifene | The serum concentration of 19-norandrostenedione can be increased when it is combined with Bazedoxifene. | Approved, Investigational |
| Bendroflumethiazide | 19-norandrostenedione may increase the hypokalemic activities of Bendroflumethiazide. | Approved |
| Benoxaprofen | The risk or severity of adverse effects can be increased when Benoxaprofen is combined with 19-norandrostenedione. | Withdrawn |
| Benzoic Acid | The therapeutic efficacy of Benzoic Acid can be decreased when used in combination with 19-norandrostenedione. | Approved |
| Betulinic Acid | The risk or severity of adverse effects can be increased when Betulinic Acid is combined with 19-norandrostenedione. | Investigational |
| Bismuth Subcitrate | The bioavailability of 19-norandrostenedione can be decreased when combined with Bismuth Subcitrate. | Approved |
| Boceprevir | The serum concentration of 19-norandrostenedione can be increased when it is combined with Boceprevir. | Approved, Investigational |
| Bromfenac | The risk or severity of adverse effects can be increased when Bromfenac is combined with 19-norandrostenedione. | Approved |
| Bumetanide | 19-norandrostenedione may increase the hypokalemic activities of Bumetanide. | Approved |
| Calcitriol | The therapeutic efficacy of Calcitriol can be decreased when used in combination with 19-norandrostenedione. | Approved, Nutraceutical |
| Calcium carbonate | The bioavailability of 19-norandrostenedione can be decreased when combined with Calcium carbonate. | Approved |
| Carbamazepine | The serum concentration of 19-norandrostenedione can be decreased when it is combined with Carbamazepine. | Approved, Investigational |
| Carprofen | The risk or severity of adverse effects can be increased when Carprofen is combined with 19-norandrostenedione. | Approved, Vet Approved, Withdrawn |
| Castanospermine | The risk or severity of adverse effects can be increased when Castanospermine is combined with 19-norandrostenedione. | Experimental |
| Celecoxib | The risk or severity of adverse effects can be increased when Celecoxib is combined with 19-norandrostenedione. | Approved, Investigational |
| Ceritinib | 19-norandrostenedione may increase the hyperglycemic activities of Ceritinib. | Approved |
| Chloroquine | The risk or severity of adverse effects can be increased when Chloroquine is combined with 19-norandrostenedione. | Approved, Vet Approved |
| Chlorothiazide | 19-norandrostenedione may increase the hypokalemic activities of Chlorothiazide. | Approved, Vet Approved |
| Chlorotrianisene | The serum concentration of 19-norandrostenedione can be increased when it is combined with Chlorotrianisene. | Withdrawn |
| Chlorthalidone | 19-norandrostenedione may increase the hypokalemic activities of Chlorthalidone. | Approved |
| Cholestyramine | Cholestyramine can cause a decrease in the absorption of 19-norandrostenedione resulting in a reduced serum concentration and potentially a decrease in efficacy. | Approved |
| Cinoxacin | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Cinoxacin. | Approved, Withdrawn |
| Ciprofloxacin | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ciprofloxacin. | Approved, Investigational |
| Clarithromycin | The serum concentration of 19-norandrostenedione can be increased when it is combined with Clarithromycin. | Approved |
| Clonixin | The risk or severity of adverse effects can be increased when Clonixin is combined with 19-norandrostenedione. | Approved |
| Cobicistat | The serum concentration of 19-norandrostenedione can be increased when it is combined with Cobicistat. | Approved |
| Colesevelam | Colesevelam can cause a decrease in the absorption of 19-norandrostenedione resulting in a reduced serum concentration and potentially a decrease in efficacy. | Approved |
| Colestipol | Colestipol can cause a decrease in the absorption of 19-norandrostenedione resulting in a reduced serum concentration and potentially a decrease in efficacy. | Approved |
| Conjugated Equine Estrogens | The serum concentration of 19-norandrostenedione can be increased when it is combined with Conjugated Equine Estrogens. | Approved |
| Corticorelin ovine triflutate | The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with 19-norandrostenedione. | Approved |
| Darunavir | The serum concentration of 19-norandrostenedione can be increased when it is combined with Darunavir. | Approved |
| Decamethonium | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Decamethonium. | Approved |
| Deferasirox | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Deferasirox. | Approved, Investigational |
| Demecarium | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Demecarium. | Approved |
| Diclofenac | The risk or severity of adverse effects can be increased when Diclofenac is combined with 19-norandrostenedione. | Approved, Vet Approved |
| Dienestrol | The serum concentration of 19-norandrostenedione can be increased when it is combined with Dienestrol. | Approved |
| Diethylstilbestrol | The serum concentration of 19-norandrostenedione can be increased when it is combined with Diethylstilbestrol. | Approved |
| Diflunisal | The risk or severity of adverse effects can be increased when Diflunisal is combined with 19-norandrostenedione. | Approved |
| Dihydrotestosterone | 19-norandrostenedione may increase the fluid retaining activities of Dihydrotestosterone. | Illicit |
| Donepezil | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Donepezil. | Approved |
| Droxicam | The risk or severity of adverse effects can be increased when Droxicam is combined with 19-norandrostenedione. | Approved |
| Echothiophate | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Echothiophate. | Approved |
| Edrophonium | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Edrophonium. | Approved |
| Enoxacin | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Enoxacin. | Approved |
| Enzalutamide | The serum concentration of 19-norandrostenedione can be decreased when it is combined with Enzalutamide. | Approved |
| Epirizole | The risk or severity of adverse effects can be increased when Epirizole is combined with 19-norandrostenedione. | Approved |
| Estradiol | The serum concentration of 19-norandrostenedione can be increased when it is combined with Estradiol. | Approved, Investigational, Vet Approved |
| Estriol | The serum concentration of 19-norandrostenedione can be increased when it is combined with Estriol. | Approved, Vet Approved |
| Estrone | The serum concentration of 19-norandrostenedione can be increased when it is combined with Estrone. | Approved |
| Etacrynic acid | 19-norandrostenedione may increase the hypokalemic activities of Etacrynic acid. | Approved |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with 19-norandrostenedione. | Approved, Investigational |
| Ethinyl Estradiol | The serum concentration of 19-norandrostenedione can be increased when it is combined with Ethinyl Estradiol. | Approved |
| Etodolac | The risk or severity of adverse effects can be increased when Etodolac is combined with 19-norandrostenedione. | Approved, Investigational, Vet Approved |
| Etofenamate | The risk or severity of adverse effects can be increased when Etofenamate is combined with 19-norandrostenedione. | Approved |
| Etoricoxib | The risk or severity of adverse effects can be increased when Etoricoxib is combined with 19-norandrostenedione. | Approved, Investigational |
| Fenbufen | The risk or severity of adverse effects can be increased when Fenbufen is combined with 19-norandrostenedione. | Approved |
| Fenoprofen | The risk or severity of adverse effects can be increased when Fenoprofen is combined with 19-norandrostenedione. | Approved |
| Fleroxacin | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Fleroxacin. | Approved |
| Floctafenine | The risk or severity of adverse effects can be increased when Floctafenine is combined with 19-norandrostenedione. | Approved, Withdrawn |
| Flumequine | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Flumequine. | Withdrawn |
| Fluoxymesterone | 19-norandrostenedione may increase the fluid retaining activities of Fluoxymesterone. | Approved, Illicit |
| Flurbiprofen | The risk or severity of adverse effects can be increased when Flurbiprofen is combined with 19-norandrostenedione. | Approved, Investigational |
| Fosaprepitant | The serum concentration of 19-norandrostenedione can be increased when it is combined with Fosaprepitant. | Approved |
| Fosphenytoin | The serum concentration of 19-norandrostenedione can be decreased when it is combined with Fosphenytoin. | Approved |
| Furosemide | 19-norandrostenedione may increase the hypokalemic activities of Furosemide. | Approved, Vet Approved |
| G17DT | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with G17DT. | Investigational |
| Galantamine | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Galantamine. | Approved |
| Gallamine Triethiodide | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Gallamine Triethiodide. | Approved |
| Gatifloxacin | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Gatifloxacin. | Approved, Investigational |
| Gemifloxacin | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Gemifloxacin. | Approved, Investigational |
| Genistein | The serum concentration of 19-norandrostenedione can be increased when it is combined with Genistein. | Investigational |
| Ginkgo biloba | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ginkgo biloba. | Approved, Nutraceutical |
| Glycerol Phenylbutyrate | The therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with 19-norandrostenedione. | Approved |
| Grepafloxacin | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Grepafloxacin. | Withdrawn |
| Hexestrol | The serum concentration of 19-norandrostenedione can be increased when it is combined with Hexestrol. | Withdrawn |
| Huperzine A | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Huperzine A. | Investigational |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with 19-norandrostenedione. | Approved, Investigational |
| Hydrochlorothiazide | 19-norandrostenedione may increase the hypokalemic activities of Hydrochlorothiazide. | Approved, Vet Approved |
| Hydroflumethiazide | 19-norandrostenedione may increase the hypokalemic activities of Hydroflumethiazide. | Approved |
| Ibuprofen | The risk or severity of adverse effects can be increased when Ibuprofen is combined with 19-norandrostenedione. | Approved |
| Ibuproxam | The risk or severity of adverse effects can be increased when Ibuproxam is combined with 19-norandrostenedione. | Withdrawn |
| Icatibant | The risk or severity of adverse effects can be increased when Icatibant is combined with 19-norandrostenedione. | Approved |
| Idelalisib | The serum concentration of 19-norandrostenedione can be increased when it is combined with Idelalisib. | Approved |
| Indacaterol | Indacaterol may increase the hypokalemic activities of 19-norandrostenedione. | Approved |
| Indapamide | 19-norandrostenedione may increase the hypokalemic activities of Indapamide. | Approved |
| Indinavir | The serum concentration of 19-norandrostenedione can be increased when it is combined with Indinavir. | Approved |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with 19-norandrostenedione. | Approved, Investigational |
| Indoprofen | The risk or severity of adverse effects can be increased when Indoprofen is combined with 19-norandrostenedione. | Withdrawn |
| INGN 201 | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with INGN 201. | Investigational |
| INGN 225 | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with INGN 225. | Investigational |
| Isoflurophate | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Isoflurophate. | Approved, Withdrawn |
| Isoniazid | The serum concentration of Isoniazid can be decreased when it is combined with 19-norandrostenedione. | Approved |
| Isoxicam | The risk or severity of adverse effects can be increased when Isoxicam is combined with 19-norandrostenedione. | Withdrawn |
| Itraconazole | The serum concentration of 19-norandrostenedione can be increased when it is combined with Itraconazole. | Approved, Investigational |
| Kebuzone | The risk or severity of adverse effects can be increased when Kebuzone is combined with 19-norandrostenedione. | Experimental |
| Ketoconazole | The serum concentration of 19-norandrostenedione can be increased when it is combined with Ketoconazole. | Approved, Investigational |
| Ketoprofen | The risk or severity of adverse effects can be increased when Ketoprofen is combined with 19-norandrostenedione. | Approved, Vet Approved |
| Ketorolac | The risk or severity of adverse effects can be increased when Ketorolac is combined with 19-norandrostenedione. | Approved |
| Leflunomide | The risk or severity of adverse effects can be increased when Leflunomide is combined with 19-norandrostenedione. | Approved, Investigational |
| Levofloxacin | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Levofloxacin. | Approved, Investigational |
| Lomefloxacin | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Lomefloxacin. | Approved |
| Lopinavir | The serum concentration of 19-norandrostenedione can be increased when it is combined with Lopinavir. | Approved |
| Lornoxicam | The risk or severity of adverse effects can be increased when Lornoxicam is combined with 19-norandrostenedione. | Approved |
| Loxoprofen | The risk or severity of adverse effects can be increased when Loxoprofen is combined with 19-norandrostenedione. | Approved |
| Lumacaftor | The serum concentration of 19-norandrostenedione can be decreased when it is combined with Lumacaftor. | Approved |
| Lumiracoxib | The risk or severity of adverse effects can be increased when Lumiracoxib is combined with 19-norandrostenedione. | Approved, Investigational |
| Magaldrate | The bioavailability of 19-norandrostenedione can be decreased when combined with Magaldrate. | Withdrawn |
| Magnesium carbonate | The bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium carbonate. | Approved |
| Magnesium Hydroxide | The bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium hydroxide. | Approved |
| Magnesium oxide | The bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium oxide. | Approved |
| Magnesium salicylate | The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with 19-norandrostenedione. | Approved |
| Magnesium Trisilicate | The bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium Trisilicate. | Approved |
| Malathion | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Malathion. | Approved, Investigational |
| Masoprocol | The risk or severity of adverse effects can be increased when Masoprocol is combined with 19-norandrostenedione. | Approved |
| Meclofenamic acid | The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with 19-norandrostenedione. | Approved, Vet Approved |
| Mefenamic acid | The risk or severity of adverse effects can be increased when Mefenamic acid is combined with 19-norandrostenedione. | Approved |
| Mefloquine | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Mefloquine. | Approved |
| Meloxicam | The risk or severity of adverse effects can be increased when Meloxicam is combined with 19-norandrostenedione. | Approved, Vet Approved |
| Memantine | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Memantine. | Approved, Investigational |
| Mesalazine | The risk or severity of adverse effects can be increased when Mesalazine is combined with 19-norandrostenedione. | Approved |
| Mestranol | The serum concentration of 19-norandrostenedione can be increased when it is combined with Mestranol. | Approved |
| Metamizole | The risk or severity of adverse effects can be increased when Metamizole is combined with 19-norandrostenedione. | Withdrawn |
| Methallenestril | The serum concentration of 19-norandrostenedione can be increased when it is combined with Methallenestril. | Experimental |
| Methyclothiazide | 19-norandrostenedione may increase the hypokalemic activities of Methyclothiazide. | Approved |
| Methyltestosterone | 19-norandrostenedione may increase the fluid retaining activities of Methyltestosterone. | Approved |
| Metolazone | 19-norandrostenedione may increase the hypokalemic activities of Metolazone. | Approved |
| Mifepristone | The therapeutic efficacy of 19-norandrostenedione can be decreased when used in combination with Mifepristone. | Approved, Investigational |
| Minaprine | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Minaprine. | Approved |
| Mitotane | The serum concentration of 19-norandrostenedione can be decreased when it is combined with Mitotane. | Approved |
| Mivacurium | Mivacurium may increase the adverse neuromuscular activities of 19-norandrostenedione. | Approved |
| Moxifloxacin | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Moxifloxacin. | Approved, Investigational |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with 19-norandrostenedione. | Approved, Investigational |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with 19-norandrostenedione. | Approved |
| Nabumetone | The risk or severity of adverse effects can be increased when Nabumetone is combined with 19-norandrostenedione. | Approved |
| Nafamostat | The risk or severity of adverse effects can be increased when Nafamostat is combined with 19-norandrostenedione. | Approved, Investigational |
| Naftifine | The risk or severity of adverse effects can be increased when Naftifine is combined with 19-norandrostenedione. | Approved |
| Nalidixic Acid | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Nalidixic Acid. | Approved |
| Naproxen | The risk or severity of adverse effects can be increased when Naproxen is combined with 19-norandrostenedione. | Approved, Vet Approved |
| NCX 4016 | The risk or severity of adverse effects can be increased when NCX 4016 is combined with 19-norandrostenedione. | Investigational |
| Nefazodone | The serum concentration of 19-norandrostenedione can be increased when it is combined with Nefazodone. | Approved, Withdrawn |
| Nelfinavir | The serum concentration of 19-norandrostenedione can be increased when it is combined with Nelfinavir. | Approved |
| Neostigmine | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Neostigmine. | Approved, Vet Approved |
| Nepafenac | The risk or severity of adverse effects can be increased when Nepafenac is combined with 19-norandrostenedione. | Approved |
| Nevirapine | The serum concentration of 19-norandrostenedione can be decreased when it is combined with Nevirapine. | Approved |
| Nicorandil | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Nicorandil. | Approved |
| Niflumic Acid | The risk or severity of adverse effects can be increased when Niflumic Acid is combined with 19-norandrostenedione. | Approved |
| Nimesulide | The risk or severity of adverse effects can be increased when Nimesulide is combined with 19-norandrostenedione. | Approved, Withdrawn |
| Norfloxacin | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Norfloxacin. | Approved |
| Ofloxacin | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ofloxacin. | Approved |
| Olopatadine | The risk or severity of adverse effects can be increased when Olopatadine is combined with 19-norandrostenedione. | Approved |
| Olsalazine | The risk or severity of adverse effects can be increased when Olsalazine is combined with 19-norandrostenedione. | Approved |
| Oxandrolone | 19-norandrostenedione may increase the fluid retaining activities of Oxandrolone. | Approved, Investigational |
| Oxaprozin | The risk or severity of adverse effects can be increased when Oxaprozin is combined with 19-norandrostenedione. | Approved |
| Oxymetholone | 19-norandrostenedione may increase the fluid retaining activities of Oxymetholone. | Approved, Illicit |
| Oxyphenbutazone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with 19-norandrostenedione. | Withdrawn |
| Parecoxib | The risk or severity of adverse effects can be increased when Parecoxib is combined with 19-norandrostenedione. | Approved |
| Pefloxacin | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Pefloxacin. | Approved |
| Pentobarbital | The serum concentration of 19-norandrostenedione can be decreased when it is combined with Pentobarbital. | Approved, Vet Approved |
| Phenobarbital | The serum concentration of 19-norandrostenedione can be decreased when it is combined with Phenobarbital. | Approved |
| Phenylacetic acid | The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with 19-norandrostenedione. | Approved |
| Phenylbutazone | The risk or severity of adverse effects can be increased when Phenylbutazone is combined with 19-norandrostenedione. | Approved, Vet Approved |
| Phenylbutyric acid | The therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with 19-norandrostenedione. | Approved, Investigational |
| Phenytoin | The serum concentration of 19-norandrostenedione can be decreased when it is combined with Phenytoin. | Approved, Vet Approved |
| Physostigmine | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Physostigmine. | Approved |
| Pimecrolimus | The risk or severity of adverse effects can be increased when Pimecrolimus is combined with 19-norandrostenedione. | Approved, Investigational |
| Piretanide | 19-norandrostenedione may increase the hypokalemic activities of Piretanide. | Experimental |
| Pirfenidone | The risk or severity of adverse effects can be increased when Pirfenidone is combined with 19-norandrostenedione. | Investigational |
| Piroxicam | The risk or severity of adverse effects can be increased when Piroxicam is combined with 19-norandrostenedione. | Approved, Investigational |
| Polythiazide | 19-norandrostenedione may increase the hypokalemic activities of Polythiazide. | Approved |
| Posaconazole | The serum concentration of 19-norandrostenedione can be increased when it is combined with Posaconazole. | Approved, Investigational, Vet Approved |
| Primidone | The serum concentration of 19-norandrostenedione can be decreased when it is combined with Primidone. | Approved, Vet Approved |
| Propacetamol | The risk or severity of adverse effects can be increased when Propacetamol is combined with 19-norandrostenedione. | Approved |
| PTC299 | The risk or severity of adverse effects can be increased when PTC299 is combined with 19-norandrostenedione. | Investigational |
| Pyridostigmine | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Pyridostigmine. | Approved |
| Quinestrol | The serum concentration of 19-norandrostenedione can be increased when it is combined with Quinestrol. | Approved |
| Quinethazone | 19-norandrostenedione may increase the hypokalemic activities of Quinethazone. | Approved |
| Rapacuronium | Rapacuronium may increase the adverse neuromuscular activities of 19-norandrostenedione. | Withdrawn |
| Resveratrol | The risk or severity of adverse effects can be increased when Resveratrol is combined with 19-norandrostenedione. | Experimental, Investigational |
| Rifabutin | The serum concentration of 19-norandrostenedione can be decreased when it is combined with Rifabutin. | Approved |
| Rifampicin | The serum concentration of 19-norandrostenedione can be decreased when it is combined with Rifampicin. | Approved |
| Rifapentine | The serum concentration of 19-norandrostenedione can be decreased when it is combined with Rifapentine. | Approved |
| Rindopepimut | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with CDX-110. | Investigational |
| Ritonavir | The serum concentration of 19-norandrostenedione can be increased when it is combined with Ritonavir. | Approved, Investigational |
| Rivastigmine | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rivastigmine. | Approved, Investigational |
| Rofecoxib | The risk or severity of adverse effects can be increased when Rofecoxib is combined with 19-norandrostenedione. | Investigational, Withdrawn |
| Rosoxacin | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rosoxacin. | Approved |
| Salicylamide | The risk or severity of adverse effects can be increased when Salicylamide is combined with 19-norandrostenedione. | Approved |
| Salicylic acid | The risk or severity of adverse effects can be increased when Salicylic acid is combined with 19-norandrostenedione. | Approved, Vet Approved |
| Salsalate | The risk or severity of adverse effects can be increased when Salsalate is combined with 19-norandrostenedione. | Approved |
| Saquinavir | The serum concentration of 19-norandrostenedione can be increased when it is combined with Saquinavir. | Approved, Investigational |
| Sparfloxacin | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Sparfloxacin. | Approved |
| SRP 299 | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with SRP 299. | Investigational |
| SRT501 | The risk or severity of adverse effects can be increased when SRT501 is combined with 19-norandrostenedione. | Investigational |
| St. John's Wort | The serum concentration of 19-norandrostenedione can be decreased when it is combined with St. John's Wort. | Nutraceutical |
| Stanozolol | 19-norandrostenedione may increase the fluid retaining activities of Stanozolol. | Approved, Vet Approved |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with 19-norandrostenedione. | Approved |
| Sulindac | The risk or severity of adverse effects can be increased when Sulindac is combined with 19-norandrostenedione. | Approved |
| Suprofen | The risk or severity of adverse effects can be increased when Suprofen is combined with 19-norandrostenedione. | Approved, Withdrawn |
| Synthetic Conjugated Estrogens, A | The serum concentration of 19-norandrostenedione can be increased when it is combined with Synthetic Conjugated Estrogens, A. | Approved |
| Synthetic Conjugated Estrogens, B | The serum concentration of 19-norandrostenedione can be increased when it is combined with Synthetic Conjugated Estrogens, B. | Approved |
| Tacrine | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Tacrine. | Withdrawn |
| Telaprevir | The serum concentration of Telaprevir can be decreased when it is combined with 19-norandrostenedione. | Withdrawn |
| Telithromycin | The serum concentration of 19-norandrostenedione can be increased when it is combined with Telithromycin. | Approved |
| Temafloxacin | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Temafloxacin. | Withdrawn |
| Tenoxicam | The risk or severity of adverse effects can be increased when Tenoxicam is combined with 19-norandrostenedione. | Approved |
| Teriflunomide | The risk or severity of adverse effects can be increased when Teriflunomide is combined with 19-norandrostenedione. | Approved |
| Testosterone | 19-norandrostenedione may increase the fluid retaining activities of Testosterone. | Approved, Investigational |
| Tiaprofenic acid | The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with 19-norandrostenedione. | Approved |
| Tibolone | The serum concentration of 19-norandrostenedione can be increased when it is combined with Tibolone. | Approved |
| Tolfenamic Acid | The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with 19-norandrostenedione. | Approved |
| Tolmetin | The risk or severity of adverse effects can be increased when Tolmetin is combined with 19-norandrostenedione. | Approved |
| Torasemide | 19-norandrostenedione may increase the hypokalemic activities of Torasemide. | Approved |
| Tranilast | The risk or severity of adverse effects can be increased when Tranilast is combined with 19-norandrostenedione. | Approved, Investigational |
| Trichlormethiazide | 19-norandrostenedione may increase the hypokalemic activities of Trichlormethiazide. | Approved, Vet Approved |
| Trisalicylate-choline | The risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with 19-norandrostenedione. | Approved |
| Trovafloxacin | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Trovafloxacin. | Approved, Withdrawn |
| Tubocurarine | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Tubocurarine. | Approved |
| Valdecoxib | The risk or severity of adverse effects can be increased when Valdecoxib is combined with 19-norandrostenedione. | Investigational, Withdrawn |
| Voriconazole | The serum concentration of 19-norandrostenedione can be increased when it is combined with Voriconazole. | Approved, Investigational |
| Warfarin | 19-norandrostenedione may increase the anticoagulant activities of Warfarin. | Approved |
| Zaltoprofen | The risk or severity of adverse effects can be increased when Zaltoprofen is combined with 19-norandrostenedione. | Approved |
| Zileuton | The risk or severity of adverse effects can be increased when Zileuton is combined with 19-norandrostenedione. | Approved, Investigational, Withdrawn |
| Zomepirac | The risk or severity of adverse effects can be increased when Zomepirac is combined with 19-norandrostenedione. | Withdrawn |
